- Home
- NUS vs CADL Comparison
NUS vs CADL Comparison
Compare NUS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- CADL
- Stock Information
- Founded
- NUS 1984
- CADL 1999
- Country
- NUS United States
- CADL United States
- Employees
- NUS N/A
- CADL N/A
- Industry
- NUS Other Pharmaceuticals
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- CADL Health Care
- Exchange
- NUS Nasdaq
- CADL Nasdaq
- Market Cap
- NUS 596.0M
- CADL 313.5M
- IPO Year
- NUS 1996
- CADL 2021
- Fundamental
- Price
- NUS $11.85
- CADL $4.84
- Analyst Decision
- NUS Hold
- CADL Strong Buy
- Analyst Count
- NUS 2
- CADL 5
- Target Price
- NUS $6.88
- CADL $19.80
- AVG Volume (30 Days)
- NUS 482.2K
- CADL 697.1K
- Earning Date
- NUS 11-06-2025
- CADL 11-13-2025
- Dividend Yield
- NUS 2.02%
- CADL N/A
- EPS Growth
- NUS N/A
- CADL N/A
- EPS
- NUS 2.03
- CADL N/A
- Revenue
- NUS $1,626,325,000.00
- CADL N/A
- Revenue This Year
- NUS N/A
- CADL N/A
- Revenue Next Year
- NUS $0.98
- CADL N/A
- P/E Ratio
- NUS $5.86
- CADL N/A
- Revenue Growth
- NUS N/A
- CADL N/A
- 52 Week Low
- NUS $5.32
- CADL $3.79
- 52 Week High
- NUS $12.41
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- NUS 58.15
- CADL 34.62
- Support Level
- NUS $11.60
- CADL $4.60
- Resistance Level
- NUS $12.10
- CADL $5.01
- Average True Range (ATR)
- NUS 0.43
- CADL 0.29
- MACD
- NUS -0.13
- CADL -0.04
- Stochastic Oscillator
- NUS 50.94
- CADL 15.28
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.